PMA device
Pipeline Vantage Embolization Device with Shield Technology
Micro Therapeutics, Inc. d/b/a ev3 Neurovascular · Intracranial Aneurysm Flow Diverter (OUT, Class III) · First FDA decision Sep 15, 2023, newest Aug 14, 2025Brain aneurysm
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
3
Naming "Pipeline Vantage Embolization"
MAUDE reports
0
Brand "Pipeline Vantage Embolization", since 2015
PubMed studies
12
Mentioning "Pipeline Vantage Embolization"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Pipeline Vantage Embolization Device with Shield Technology
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
P100018-S048 · Decided Aug 14, 2025 · 197 days after receipt · Normal 180 Day Track No User Fee
Device type: Intracranial aneurysm flow diverter (OUT) · Neurology & Neurosurgery
P100018-S043 · Decided Jun 6, 2024 · 237 days after receipt · Normal 180 Day Track No User Fee
Device type: Intracranial aneurysm flow diverter (OUT) · Neurology & Neurosurgery
P100018-S034 · Decided Sep 15, 2023 · 718 days after receipt · Normal 180 Day Track
Device type: Intracranial aneurysm flow diverter (OUT) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Pipeline Vantage Embolization", any status and sponsor, newest update first.
Medtronic Neurovascular Clinical AffairsPublic (MDT)
NCT06604884 · 118 participants (planned) · Start Dec 12, 2025 · Primary completion Aug 2029
Device: Treatment of Intracranial Aneurysms · For: Intracranial Aneurysm
Sites: Jacksonville, Florida; Marietta, Georgia; Evanston, Illinois · 10 sites in all
Medtronic Neurovascular Clinical AffairsPublic (MDT)
NCT03873714 · 14 participants · Start Apr 2, 2020 · Primary completion Jul 22, 2021
Device: Pipeline™ Vantage Embolization Device with Shield Technology™ · For: Intracranial Aneurysm
Sites: Jacksonville, Florida; Miami, Florida; Stony Brook, New York
- Outcome Study of the Pipeline Embolization Device With Vantage Technology in Unruptured AneurysmsStatus unknown
King's College Hospital NHS TrustAcademic, hospital or other
NCT05626504 · 50 participants (planned) · Start Oct 27, 2022 · Primary completion Mar 1, 2025
Device: Pipeline Embolization Device with Vantage Technology · For: Brain Aneurysm; Intracranial Hemorrhages; Stroke
Sites: London, United Kingdom
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Pipeline Vantage Embolization", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OUT
10,961 reports: 7,308 malfunction, 3,152 injury, 499 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1245-2025 · Started Jan 30, 2025 · Posted by FDA Mar 5, 2025
Reason given: Use of embolization device with diameters greater-than-or-equal-to 4mm may lead to incomplete wall apposition and/or braid deformation (fish-mouthing/braid narrowing/braid collapse) noted during procedure and post-procedure, typically noted at 6-12 month imaging follow-up, potentially can lead to thrombosis and/or...
Cause as FDA categorized it: Device Design · Device type: Intracranial Aneurysm Flow Diverter (OUT)
Z-1246-2025 · Started Jan 30, 2025 · Posted by FDA Mar 5, 2025
Reason given: Use of embolization device with diameters greater-than-or-equal-to 4mm may lead to incomplete wall apposition and/or braid deformation (fish-mouthing/braid narrowing/braid collapse) noted during procedure and post-procedure, typically noted at 6-12 month imaging follow-up, potentially can lead to thrombosis and/or...
Cause as FDA categorized it: Device Design · Device type: Intracranial Aneurysm Flow Diverter (OUT)
- Pipeline Flex Embolization DeviceOpen, Classified
Z-2402-2021 · Started Jul 13, 2021
Reason given: Due to potential push wire fractures in the delivery system during use. The issue presents as a fracture in the spiral cut area of the Hypotube.
Cause as FDA categorized it: Device Design · Device type: Intracranial Aneurysm Flow Diverter (OUT)
9 more recall records with a free account
Published research
The most relevant PubMed records for "Pipeline Vantage Embolization"[tiab]. The summary above synthesizes these.
- Outcome study of the Pipeline Vantage Embolization Device (second version) in unruptured (and ruptured) aneurysms (PEDVU(R) study).
Booth TC, Bassiouny A, Lynch J, et al. · J Neurointerv Surg · 2024Multicenter Study
- Aneurysm Treatment With the Pipeline Vantage Embolization Device in Retrospective Evaluation: Periprocedural Results from the Pipe-VADER Study.
Goertz L, Pflaeging M, Gronemann C, et al. · World Neurosurg · 2024Observational Study
- Midterm Results on Pipeline Vantage Embolization Device (MR-PVED): First Reported Experience in Asia.
Chan SK, Ho LY, Lam SKS, et al. · Asian J Neurosurg · 2026
- Telescoping pipeline vantage embolization devices with shield technology for the treatment of a giant, symptomatic dolichoectatic basilar trunk aneurysm.
Hackett AM, Luther EM, Walker AP, et al. · Surg Neurol Int · 2022Case Reports
- Pipeline Vantage Embolization Device for the treatment of intracranial aneurysms: A systematic review and meta-analysis.
Goertz L, Hohenstatt S, Zopfs D, et al. · Interv Neuroradiol · 2026Systematic Review, Meta-Analysis
- Preclinical safety and efficacy evaluation of the Pipeline Vantage Embolization Device with Shield Technology.
Starke RM, Thompson J, Pagani A, et al. · J Neurointerv Surg · 2020
- Early Outcomes of the Pipeline Vantage Flow Diverter : A Multicentre Study.
Sciacca S, Bassiouny A, Mansoor N, et al. · Clin Neuroradiol · 2023Review
- Fourth-generation Pipelineࡊ Vantage flow diversion: First reported US experience of safety and feasibility.
Sweid A, Chahine A, Hage S, et al. · Interv Neuroradiol · 2026
- Software-based simulation for pipeline vantage flow diverter preprocedural assessment: Method and validation study.
Sanders JV, Oliver M, Obradó L, et al. · Interv Neuroradiol · 2025
- RECOAT study - Retrospective evaluation of surface-modified and coated flow diverters for the treatment of unruptured intracranial aneurysms.
Goertz L, Hohenstatt S, Vollherbst DF, et al. · Neuroradiology · 2026Multicenter Study
- Efficacy and Safety in the Use of Pipeline Vantage Shield Stent versus Pipeline Flex Shield Stent in the Treatment of Patients with Unruptured Intracranial Aneurysms: A Multicenter Study.
Catalá AJ, Ortiz-Giraldo AF, Estévez-Ochoa MF, et al. · AJNR Am J Neuroradiol · 2025Multicenter Study, Comparative Study
- Flow diversion of a distal M3 segment middle cerebral artery pseudoaneurysm in a pediatric patient: illustrative case.
Cuoco JA, Gruber MD, Sribnick EA, et al. · J Neurosurg Case Lessons · 2026
Other devices of this type
Also filed under product code OUT.
- Pipeline Flex Embolization Device with Shield TechnologyMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2021
- Flow Re-Direction Endoluminal Device (FRED®) SystemMicroVention, Inc. · PMA 2025
- Pipeline Embolization Devices,pipeline Flex Embolization DeviceMicro Therapeutics, Inc. d/b/a ev3 Neurovascular · PMA 2015
- Surpass Streamline Flow DiverterStryker Neurovascular · PMA 2022
- Surpass Elite Flow Diverter SystemStryker Neurovascular · PMA 2024
- FRED X SystemMicroVention, Inc. · PMA 2022
- Surpass Evolve Flow Diverter SystemStryker Neurovascular · PMA 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.